IRF9 and breast cancer: Further, upregulation of ISGs like STAT1, STAT2, or IRF9 is known to promote cancer resistance to chemotherapy and radiotherapy as demonstrated in human head and neck squamous cell carcinoma and breast cancer [43–46].